KIM
DMII

Karpus Investment Management’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Karpus Investment Management’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28M Buy
2,787,998
+190,075
+7% +$1.91M 0.81% 28
2026
Q1 		$25.9M Buy
2,597,923
+1,454,298
+127% +$14.5M 0.81% 27
2025
Q4 		$11.3M Buy
+1,143,625
New +$11.3M 0.35% 75

Other funds holding DMII

MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Karpus Investment Management's DMII Position: Q2 2026 in Review

Karpus Investment Management increased its Drugs Made In America Acquisition II Corp (DMII) stake by 7.3% in Q2 2026, buying an estimated $1.91M and bringing the position to 2,787,998 shares worth $28M. The position accounts for 0.81% of the portfolio, ranked #28.

Karpus Investment Management first reported a position in DMII in Q4 2025 and has held it in 3 quarters since. 69 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • Karpus Investment Management held 2,787,998 shares of Drugs Made In America Acquisition II Corp worth $28M as of Q2 2026.
  • Karpus Investment Management bought 190,075 Drugs Made In America Acquisition II Corp shares in Q2 2026, an estimated $1.91M.
  • Drugs Made In America Acquisition II Corp made up 0.81% of Karpus Investment Management's portfolio in Q2 2026, its #28 holding.
  • Karpus Investment Management first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 3 quarters since.
  • 69 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on Karpus Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.